Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Overview: ImmuCell develops, acquires, manufactures, and sells products to improve the health and productivity of cows for the dairy and beef industries. The company operates in a single reportable segment. Its primary products include First Defense (a preventative vaccine for bovine enteritis) and Wipe Out Dairy Wipes. The company is currently focusing significant resources on the internal development of Mast Out, a mastitis treatment, following the termination of a development agreement with Pfizer in July 2007.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2008 | Six Months Ended June 30, 2007 |
|---|---|---|
| Total Revenues | $2,461,925 | $2,634,514 |
| Product Sales | $2,457,144 | $2,299,719 |
| Net Income (Loss) | $(160,124) | $236,523 |
| Net Income (Loss) Per Share (Basic) | $(0.06) | $0.08 |
| Cash and Cash Equivalents | $1,272,438 | $1,192,637 |
| Short-term Investments | $4,422,465 | $4,218,880 |
| Total Current Assets | $7,095,956 | $7,065,361 |
| Total Current Liabilities | $350,348 | $355,517 |
| Net Working Capital | $6,745,608 | $6,709,844 |
| Net Cash Provided by Operating Activities | $417,440 | $164,665 |
| Stockholders' Equity | $9,951,173 | $10,056,971 |
Debt and Liquidity: The company has no outstanding bank debt. Total liquid assets (cash, cash equivalents, and short-term investments) totaled approximately $5.7 million as of June 30, 2008.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 7% ($172,589) compared to the prior six-month period. This decline was driven by the absence of technology licensing revenue ($316,288 in 2007 vs. $0 in 2008) following the termination of the Pfizer agreement. Product sales, however, increased by 7% ($157,425).
- Profitability Shift: The company reported a net loss of $160,124 for the six months ended June 30, 2008, compared to a net income of $236,523 in the same period in 2007. This marks the end of nine consecutive years of profitability.
- Expense Increases: Product development expenses increased by 35% ($195,299) to $755,248. This increase reflects the shift from Pfizer-funded development to internal funding for the Mast Out program. General and administrative expenses rose 23% due to compensation and compliance costs.
- Gross Margin: Gross margin as a percentage of product sales remained relatively stable at 49% for the six-month period (down slightly from 50% in 2007), despite rising raw material costs.
Guidance, Outlook, and Risks
Management Commentary and Outlook: Management projects a loss before income taxes for the full year 2008 of approximately $500,000 to $750,000. This projection is primarily due to increased internal spending on the development of Mast Out. The company believes it has sufficient capital resources (approx. $5.7 million in liquid assets) to fund operations and development for at least the next twelve months. The company is actively seeking collaborative partnerships to share the costs and risks of bringing Mast Out to market.
Key Risks and Contingencies:
- Regulatory Approval: Commercialization of Mast Out is contingent upon FDA approval, specifically regarding a "zero milk discard" claim. There is no assurance that approval will be granted or when it will occur.
- Product Concentration: The company is heavily reliant on First Defense for revenue. Sales of this product are seasonal and influenced by the economic conditions of the dairy industry (milk prices vs. feed costs).
- Compliance: The company is investing in facility upgrades and personnel to achieve compliance with Current Good Manufacturing Practice (cGMP) regulations following a 2007 FDA Warning Letter. Failure to maintain compliance could disrupt operations.
- Market Competition: The mastitis treatment market is highly competitive, dominated by large pharmaceutical companies.
Investor Verification Checklist
- Capital Sufficiency: Verify if the projected $500k-$750k loss for 2008 aligns with the current cash burn rate and if the $5.7 million cash reserve is adequate to sustain operations through the pivotal Mast Out study completion (expected end of 2008) and subsequent regulatory review.
- Regulatory Timeline: Confirm the status of the pivotal effectiveness study for Mast Out initiated in June 2008 and the timeline for the submission of the New Animal Drug Application (NADA), currently targeted for the first half of 2010.
- cGMP Compliance: Review the company's progress in addressing the deficiencies cited in the June 2007 FDA Warning Letter and the status of the $775,000 facility addition authorized in June 2008.
- Customer Concentration: Assess the risk associated with the top two customers (Animal Health International and Lextron/Vet Pharm), which accounted for approximately 39% of product sales in the six months ended June 30, 2008.
- Product Mix: Monitor the sales trend of Wipe Out Dairy Wipes, which saw a 5% decline in the first half of 2008 due to competitive pricing and economic pressure on small dairy producers.